Fig 1: Attenuated tumor growth in LEC-specific MHC-II knockout background is associated with increased number of effector CD4+ TILs and decreased number of T regulatory lymphocytes. (A) Representative FACS plots and (B) quantification of CD4+cells in the tumor, tumor draining lymph node, and spleen in WT and LECMHC II-/- mice bearing B16F10-OVA at 12 days post tumor inoculation. (C) Representative FACS plots and (D) quantification of CD4+CD25+FoxP3+cells in the tumor, tumor draining lymph node, and spleen in WT and LECMHC II-/- mice bearing B16F10-OVA at 12 days post tumor inoculation. (E) Representative FACS plots and (F) quantification of GZMB+CD4+CD25-FoxP3- in the tumor, tumor draining lymph node, and spleen in WT and LECMHC II-/- mice bearing B16F10-OVA at 12 days post tumor inoculation. Statistical significance assessed using unpaired student’s t test on data from at least 5 biological replicates; error represented as SD. *, p < 0.05.